<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296244</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080AUS29</org_study_id>
    <nct_id>NCT00296244</nct_id>
  </id_info>
  <brief_title>Steroid Free Immunosuppression in Liver Transplantation</brief_title>
  <official_title>Steroid Free Immunosuppression in Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether steroid-related complications can be
      avoided by using steroid-free immuno-suppressive drug regimen after liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Steroids have remained a standard part of post-transplant immunosuppression, both for
      prevention and treatment of rejection. However, steroids have been shown to cause long-term
      adverse effects, such as: susceptibility to infection, obesity, hypertension, hyperlipidemia,
      diabetes, osteopenia, cataracts and growth retardation in children. They have also been
      implicated in accelerating Hepatitis C virus (HCV) re-infection post-liver transplantation.

      Several studies have shown that early steroid reduction or withdrawal could be done safely to
      alleviate many steroid-related adverse effects after liver transplantation (OLT).

      This is a prospective controlled randomized trial on adult patients who will undergo primary
      OLT at Thomas Jefferson University Hospital (TJUH).

      Forty consecutive OLT recipients shall be randomized into two groups.

        -  Control group- immuno-suppressive drug regimen consisting of basiliximab (Simulect),
           tacrolimus (Prograf), Mycophenolic acid (Myfortic), and steroids

        -  Study group- immuno-suppressive drug regimen consisting of basiliximab, tacrolimus,
           Mycophenolic acid (Myfortic) without steroids

      Basiliximab will be given at 20 mg IV bolus intra-operatively and on the 4th day after
      transplantation. Tacrolimus shall be administered at a dose of 0.15mg/ kg/ day by mouth or
      through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but
      within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of
      10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml,
      thereafter. Patients randomized to the control group shall be administered methylprednisolone
      (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued
      according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs
      on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs
      on day 5; and Prednisone 20 mg by mouth or NGT on day 6. Prednisone shall be tapered slowly
      starting at 1 month post-OLT and weaned off completely by 6 months post-OLT. Enteric-coated
      mycophenolic acid or EC-MPA (Myfortic) will be added to the regimen, particularly in patients
      with renal impairment or neuro-toxicity to minimize the dose and effects of tacrolimus. It
      will be started at 720 mg P.O. 2x/ day immediately post-transplant and shall be given for a
      period of 3 months.

      Primary end points of this study at 6 months post-transplant include: graft and patient
      survival rates, and incidence of acute rejection and therapy employed to treat rejection.
      Secondary end points include: adverse effects of steroids, particularly, diabetes, obesity,
      hyperlipidemia, and hypertension; incidence and severity of HCV recurrence, and incidence of
      infectious complications.

      Blood samples of HCV recipients shall be collected on day of surgery, 2 weeks, 1 month, 3
      months, and 6 months post-OLT as per TJUH Liver Transplant Protocol. Sera shall be stored at
      -80C and will be used for quantitative HCV RNA levels by quantitative polymerase chain
      reaction.

      Protocol liver biopsy shall be performed at the time of surgery, between 7-21 days post-OLT
      and at approximately 3 months after transplantation or as clinically indicated by elevated
      liver function test results.

      Acute rejection shall be treated initially by increasing the tacrolimus dose to achieve a
      level 15-20 ng/ml for 48 hrs. If liver function test results will not show improvement by the
      3rd day after increasing tacrolimus dose, a biopsy should be performed. Only biopsy proven
      rejection shall be treated according to the following protocol. Mild to moderate rejection
      shall be treated in the study group with methylprednisolone 1 gm IV with tapering doses of
      steroid as described above. Steroids shall be discontinued after the completion of the taper.
      In the control group, methylprednisolone 1 gm IV shall be followed by tapering doses and by
      prednisone 20 mg once daily, which shall be progressively reduced accordingly. The protocol
      shall also include a repeat biopsy if there is no improvement in the liver function test at
      the end of steroid taper. Severe rejection or steroid resistant rejection shall be treated
      with OKT3 at 5mg IV/ day for 5-10 days after pre-medication.

      Recipients with HCV recurrence shall be treated according to TJUH Liver Transplant protocol
      as follows. Abnormal liver function tests should be evaluated by hepatic imaging to exclude
      anatomic abnormality. If none, liver biopsy will be done. If liver biopsy shows &gt; grade 4
      (inflammation more than mild) or &gt; stage 1 (fibrosis), consider antiviral treatment
      consisting of Peg-Interferon alpha-2a 180mcg subcutaneously weekly for two weeks. If patient
      tolerates peg-interferon from hematologic and neuro-psychiatric standpoint, continue
      peg-interferon, and add ribavirin. Refer to protocol for dosing. Total duration of therapy is
      48 weeks.

      Follow up period for primary analysis will be six (6) months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Survival Rate</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Percentage of recipients whose liver grafts are still working at the end of 1 and 2 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Survival Rate</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Percentage of recipients who are still alive at the end of 1 and 2 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Rejection Rate</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>Biopsy proven acute rejection defined by biochemical and histological changes as well as the need for temporary steroid use occurred in 1 patient in each group both of which were steroid responsive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection as an Adverse Effect of Steroids</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>Incidence of bacterial infection was similar in the control group as well as study group, 4 patients in both groups had infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of HCV Recurrence Post-OLT</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>The incidence and severity of HCV recurrence based on Hepatitis C PCR levels and protocol liver biopsy findings were found to be similar between the 2 groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset Diabetes Mellitus (NODM) as Secondary Outcome</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence of new-onset Diabetes mellitus (NODM, based on percentage of previously non-diabetic patients who developed DM post-transplantation, was similar between the 2 groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Liver Transplant Disorder</condition>
  <arm_group>
    <arm_group_label>Steroid -free immunosuppression</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study group - Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid containing immunosuppression</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group- Basiliximab, Tacrolimus, EC-MPA, steroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.</description>
    <arm_group_label>Steroid containing immunosuppression</arm_group_label>
    <other_name>Methylprednisolone (Solumedrol)</other_name>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.</description>
    <arm_group_label>Steroid -free immunosuppression</arm_group_label>
    <arm_group_label>Steroid containing immunosuppression</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.</description>
    <arm_group_label>Steroid -free immunosuppression</arm_group_label>
    <arm_group_label>Steroid containing immunosuppression</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-coated Mycophenolic acid (EC-MPA)</intervention_name>
    <description>This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.</description>
    <arm_group_label>Steroid -free immunosuppression</arm_group_label>
    <arm_group_label>Steroid containing immunosuppression</arm_group_label>
    <other_name>Myfortic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between 18 and 72 years of age

          -  Male or female patients who are primary cadaveric liver transplant recipients

          -  Cold ischemia time must be &lt;20 hours

          -  Females capable of becoming pregnant must have a negative pregnancy test at baseline
             and are required to practice an approved method of birth control for the duration of
             the study and for a period of three months following discontinuation of study
             medication

          -  Patient has given written informed consent to participate in the study

        Exclusion Criteria:

          -  Patients meeting any of the following criteria at baseline will be excluded from study
             participation

          -  Patients who have previously received an organ transplant

          -  Patients who are recipients of a multiple organ transplants

          -  Women of childbearing potential not using the contraception method(s) specified in
             this study, as well as women who are breastfeeding

          -  Known sensitivity to Simulect or class of Simulect

          -  Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study

          -  Use of any other investigational agent in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Gerardo B Ramirez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <results_first_submitted>July 21, 2011</results_first_submitted>
  <results_first_submitted_qc>October 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2012</results_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>steroid-free immunosuppression</keyword>
  <keyword>liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between February 2006 and November 2007,at Thomas Jefferson University, 40 adult orthotopic liver transplantation recipients were enrolled in the study and 20 recipients were randomized in each group.</recruitment_details>
      <pre_assignment_details>One recipient in the Steroid free group required re-transplantation and died within 1 month after the 2nd OLT, and was subsequently excluded from analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Control group- basiliximab (Simulect), tacrolimus (Prograf), EC-MPA (Myfortic)with steroids</description>
        </group>
        <group group_id="P2">
          <title>Study Group</title>
          <description>Study group- basiliximab (Simulect), tacrolimus (Prograf), EC-MPA (Myfortic)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Underwent retransplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Control group -basiliximab, tacrolimus, EC-MPA, steroids</description>
        </group>
        <group group_id="B2">
          <title>Study Group</title>
          <description>Study group- basiliximab, tacrolimus, EC-MPA</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.40" spread="2.6"/>
                    <measurement group_id="B2" value="56.2" spread="1.1"/>
                    <measurement group_id="B3" value="53" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Graft Survival Rate</title>
        <description>Percentage of recipients whose liver grafts are still working at the end of 1 and 2 years.</description>
        <time_frame>1 and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group-basiliximab, tacrolimus, EC-MPA, steroids</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Study group- basiliximab, tacrolimus, EC-MPA</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Survival Rate</title>
          <description>Percentage of recipients whose liver grafts are still working at the end of 1 and 2 years.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-year graft survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-year graft survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Survival Rate</title>
        <description>Percentage of recipients who are still alive at the end of 1 and 2 years.</description>
        <time_frame>1 and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group -basiliximab, tacrolimus, EC-MPA, steroids</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Study group- basiliximab, tacrolimus, EC-MPA</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival Rate</title>
          <description>Percentage of recipients who are still alive at the end of 1 and 2 years.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-year patient survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-year patient survival rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acute Rejection Rate</title>
        <description>Biopsy proven acute rejection defined by biochemical and histological changes as well as the need for temporary steroid use occurred in 1 patient in each group both of which were steroid responsive</description>
        <time_frame>6 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group -basiliximab, tacrolimus, EC-MPA, steroids</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Study group -basiliximab, tacrolimus, EC-MPA</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Rejection Rate</title>
          <description>Biopsy proven acute rejection defined by biochemical and histological changes as well as the need for temporary steroid use occurred in 1 patient in each group both of which were steroid responsive</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection as an Adverse Effect of Steroids</title>
        <description>Incidence of bacterial infection was similar in the control group as well as study group, 4 patients in both groups had infection</description>
        <time_frame>3 months post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group)-basiliximab, tacrolimus, EC-MPA, steroids</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Study group- basiliximab, tacrolimus, EC-MPA</description>
          </group>
        </group_list>
        <measure>
          <title>Infection as an Adverse Effect of Steroids</title>
          <description>Incidence of bacterial infection was similar in the control group as well as study group, 4 patients in both groups had infection</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Severity of HCV Recurrence Post-OLT</title>
        <description>The incidence and severity of HCV recurrence based on Hepatitis C PCR levels and protocol liver biopsy findings were found to be similar between the 2 groups.</description>
        <time_frame>6 months post-transplant</time_frame>
        <population>Only patients with HCV cirrhosis as the main indication for OLT were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group)-basiliximab, tacrolimus, EC-MPA, steroids</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Study group- basiliximab, tacrolimus, EC-MPA</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of HCV Recurrence Post-OLT</title>
          <description>The incidence and severity of HCV recurrence based on Hepatitis C PCR levels and protocol liver biopsy findings were found to be similar between the 2 groups.</description>
          <population>Only patients with HCV cirrhosis as the main indication for OLT were included in this analysis</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New-onset Diabetes Mellitus (NODM) as Secondary Outcome</title>
        <description>The incidence of new-onset Diabetes mellitus (NODM, based on percentage of previously non-diabetic patients who developed DM post-transplantation, was similar between the 2 groups.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Control group- basiliximab, tacrolimus, EC-MPA, steroids</description>
          </group>
          <group group_id="O2">
            <title>Study Group</title>
            <description>Study group - basiliximab, tacrolimus, EC-MPA</description>
          </group>
        </group_list>
        <measure>
          <title>New-onset Diabetes Mellitus (NODM) as Secondary Outcome</title>
          <description>The incidence of new-onset Diabetes mellitus (NODM, based on percentage of previously non-diabetic patients who developed DM post-transplantation, was similar between the 2 groups.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse data were collected at 1 and 2 years follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Control group -basiliximab, tacrolimus, EC-MPA, steroids</description>
        </group>
        <group group_id="E2">
          <title>Study Group</title>
          <description>Study group- basiliximab, tacrolimus, EC-MPA</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>New-onset Diabetes Mellitus (NODM)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C Recurrence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute rejection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carlo Gerardo B Ramirez, MD</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215-955-5909</phone>
      <email>carlo.ramirez@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

